Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Natural Killer Cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Natural Killer Cells. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-000054-63 Sponsor Protocol Number: HNJ-NKAES-2012 Start Date*: 2012-07-25
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS
    Full Title: Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
    Medical condition: Relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000411-91 Sponsor Protocol Number: NKZellen-Version1.0 Start Date*: 2013-02-13
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial
    Medical condition: relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001929-27 Sponsor Protocol Number: NK4AML Start Date*: 2020-05-20
    Sponsor Name:Radboud University Medical Centre
    Full Title: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’
    Medical condition: AML patients who do not have rapid progressive disease with or without disease controlling medication and who are not eligible for allogeneic SCT.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001496-11 Sponsor Protocol Number: 08020 Start Date*: 2010-01-15
    Sponsor Name:University of Nottingham
    Full Title: The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple Sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003421-28 Sponsor Protocol Number: TUD-HINKL1-059 Start Date*: 2014-07-10
    Sponsor Name:Technische Universität Dreden
    Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia
    Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001901-15 Sponsor Protocol Number: NKCell_LMA_2015 Start Date*: 2016-04-01
    Sponsor Name:Antonio Pérez Martínez
    Full Title: Natural Killer cell infusion as consolidation therapy in children and adolescents with acute myelogenous leukemia.
    Medical condition: Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002130-30 Sponsor Protocol Number: NSCLC-TKD/IL-2 Start Date*: 2013-11-15
    Sponsor Name:Technische Universität München Fakultät für Medizin
    Full Title: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
    Medical condition: Interventional phase II clinical trial incorporating a parallel control group of patients receiving no adjuvant immunotherapy. Patients with non small lung cell carcinoma (NSCLC) in stage III A and...
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10006427 Bronchial carcinoma stage III LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001371-20 Sponsor Protocol Number: 18-PP-03 Start Date*: 2018-06-11
    Sponsor Name:CHU de Nice
    Full Title: Study of the role of local treatments on the modulation of the microbiome in psoriatic skin
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022627-29 Sponsor Protocol Number: IIR-HBV-2010 Start Date*: 2011-03-29
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine)
    Medical condition: Chronic HBV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003686-17 Sponsor Protocol Number: WiNK Start Date*: 2020-07-03
    Sponsor Name:Glycostem Therapeutics BV
    Full Title: A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute my...
    Medical condition: acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) FR (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000704-28 Sponsor Protocol Number: GCP#05.01.020 Start Date*: 2016-06-16
    Sponsor Name:Gamida Cell Ltd
    Full Title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10009015 Chronic myeloid leukemia LLT
    19.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001121-14 Sponsor Protocol Number: CL010_168 Start Date*: Information not available in EudraCT
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculi...
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) DK (Completed) BE (Completed) NO (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003181-32 Sponsor Protocol Number: CIMNK1001 Start Date*: 2011-10-14
    Sponsor Name:Karolinska University Hospital
    Full Title: In vivo expansion and efficacy of adoptive natural killer cell-based immunotherapy for high-risk myeloid diseases
    Medical condition: acute myeloid leukemia and myelodysplastic syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10000886 Acute myeloid leukemia LLT
    16.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003578-42 Sponsor Protocol Number: SANKOMA_2016 Start Date*: 2018-04-25
    Sponsor Name:Antonio Pérez-Martínez
    Full Title: Phase I / II Clinical Trial, multicenter, open, of infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas.
    Medical condition: Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001282-17 Sponsor Protocol Number: E7389-G000-223 Start Date*: 2018-03-23
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S...
    Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001821-42 Sponsor Protocol Number: CL011_168 Start Date*: 2018-08-02
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy
    Medical condition: C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, fo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) ES (Completed) DK (Completed) FR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005130-27 Sponsor Protocol Number: IVORY Start Date*: 2019-11-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Low-dose interleukin-2 for the reduction of vascular inflammation in Acute Coronary Syndromes (IVORY)
    Medical condition: Acute Coronary Syndrome (ACS) such as myocardial infarction and unstable angina
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004541-33 Sponsor Protocol Number: immvzmpr1 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalandsregionen
    Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
    Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004475-39 Sponsor Protocol Number: 73763989HPB2003 Start Date*: 2020-09-21
    Sponsor Name:Janssen Sciences Ireland Unlimited Company
    Full Title: A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) PL (Completed) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA